Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Down Syndrome Memantine Follow-up Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02304302
Recruitment Status : Recruiting
First Posted : December 1, 2014
Last Update Posted : October 10, 2018
Sponsor:
Collaborator:
Alana USA Foundation
Information provided by (Responsible Party):
Dr. Alberto Costa, University Hospitals Cleveland Medical Center

Brief Summary:
The purpose of this research study is to learn if the medication Memantine Hydrochloride (the study medication) can help adolescents and young adults with Down syndrome. Dr. Alberto Costa and his research team want to see if a 16-week treatment with this medication can improve the participant's ability to learn and remember things. In this study, memantine hydrochloride will be used. Thus, the researchers want to learn whether the study drug can help improve memory in young adults with Down syndrome. To test the effect of the study medicine, half of the people in the study will receive the study medicine and half will receive a placebo (an inactive substance). Memantine is an approved medication to treat memory and thinking problems in persons with Alzheimer disease. However, little is known about the effect of this medication in persons with Down syndrome and it has not been approved for use in persons with Down syndrome.

Condition or disease Intervention/treatment Phase
Down Syndrome Intellectual Disability Drug: Memantine Drug: Placebo Phase 2

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase II Multicenter 16-Week Randomized Double Blind Placebo-Controlled Evaluation of the Efficacy, Tolerability and Safety of Memantine Hydrochloride on Enhancing the Cognitive Abilities of Adolescents and Young Adults With Down Syndrome
Study Start Date : October 2014
Estimated Primary Completion Date : November 2019
Estimated Study Completion Date : December 2019


Arm Intervention/treatment
Placebo Comparator: Placebo
Identically-looking placebo pills to memantine will be dispensed in a 66-day supply (56 days plus 10 extra days) by the study coordinator to participants receiving the placebo at the end of visits 2 and 3.
Drug: Placebo
Identically looking placebo capsules bid (after a four-week regimen designed to mimic dose escalation protocol)
Other Name: Inactive Capsules

Experimental: Memantine
Memantine will be dispensed in a 66-day supply (56 days plus 10 extra days) by the study coordinator to participants receiving the placebo at the end of visits 2 and 3.
Drug: Memantine
Encapsulated Namenda 10 mg bid (after four week dose escalation protocol)
Other Name: Namenda




Primary Outcome Measures :
  1. Efficacy of the drug Memantine as assessed by the California Verbal Learning Test-II (CVLT-II) short form [ Time Frame: 3 years ]
    The primary efficacy measure is focused on episodic memory. It assesses supraspan word learning ability as an index of episodic verbal long-term memory. The choice of the appropriate measure for individuals with Down syndrome was based on results of our pilot clinical trial of the drug memantine in young adults with Down syndrome (Boada et al., 2012). We hypothesize that treatment with memantine will produce significant improvements in the CVLT-II short form. Two dependent variables were selected, based on prior literature, as indexing hippocampal function: Total number of target items correct summed across learning trials 1-4, and total free recall discriminability for the learning trials, which takes into account hits as well as false positives.


Secondary Outcome Measures :
  1. Efficacy of the drug Memantine as assessed by Paired Associates Learning (PAL) from the Cambridge Neuropsychological Test Automated Battery (CANTAB) [ Time Frame: 3 years ]
    This is a measure of non-verbal memory that requires the participant to learn associations between an abstract visual pattern and its location. Two dependent variables have been selected: Total number of items correct on the first trial of each stage, and total number of stages completed.

  2. Efficacy of the drug Memantine as assessed by Recall of Digits (Differential Ability Scales; DAS-II). [ Time Frame: 3 years ]
    This is a measure of rote short-term verbal memory. Total number of items correct will be used as the dependent variable.

  3. Efficacy of the drug Memantine as assessed by Pattern Recognition Memory (PRM; part of the CANTAB) [ Time Frame: 3 years ]
    This is a measure of non-verbal memory. Total number correct across the two series of items presented will be used as the dependent variable.

  4. Efficacy of the drug Memantine as assessed by Spatial Working Memory (part of the CANTAB) [ Time Frame: 3 years ]
    The test requires participants to search under a series of colored boxes to locate a "blue token" hidden underneath one of them. During a series of trials, the participant is told that the token will be in a new location each time and that they should not go back to a location he or she has looked in previously. Two dependent variables were selected: 1) The total number of errors ("between errors"), which indexes the number of times a participant went back to a box where a token had already been found; and 2) a "strategy" score, which indexes the number of times the participant started a search with a different box, the latter being an inefficient strategy (i.e., high strategy scores denote poorer performance).

  5. Efficacy of the drug Memantine as assessed by Spatial Span (part of the CANTAB) [ Time Frame: 3 years ]
    This measure is a computerized version of the Corsi Blocks task, a long-standing neuropsychological test. Two dependent variables were selected for this test: 1) span length, which is the longest sequence of numbers recalled accurately (possible score ranges from 2 to 9); and 2) total usage errors, which represents the number of times a subject selects a box no in the sequence being recalled.

  6. Efficacy of the drug Memantine as assessed by The Go - No Go task [ Time Frame: 3 years ]
    This is a measure of inhibitory control, often used as a marker for prefrontal-striatal function integrity. Specifically, it measures the participant's ability to inhibit pre-potent behavioral responses that have been established by provision of prior "go" or "no-go" cues in a classical conditioning paradigm. Two dependent variables were selected: 1) the proportion of no-go targets in which a subject fails to inhibit a response under the go-cue (pre-potent) condition; and 2) speed of response execution to Go targets.

  7. Safety and tolerability of the drug Memantine as assessed by the incidence of adverse events [ Time Frame: 3 years ]
    Incidence of adverse events will be monitored by clinical history, physical examinations, electrocardiograms (ECGs), clinical laboratory tests, and the Screen for Childhood Anxiety Related Emotional Disorders (SCARED).


Other Outcome Measures:
  1. Intellectual functioning of the participants as assessed by Matrices subtest of the Differential Ability Scales-II (DAS-II) [ Time Frame: 3 years ]
    This test will provide a measure of non-verbal reasoning ability that requires subjects to visually inspect a matrix of 4 or 9 pictures that has a missing piece. Participants have to infer a rule or pattern in the stimuli, and select the appropriate response from a range of 4-6 possibilities. Since age norms are not available for individuals older than 17y11m, the ability score will be used as the dependent variable. This is an intermediate score based on Rasch modeling that corrects for different items set being administered to participants.

  2. Linguistic functioning of the participants as assessed by the Test for Reception of Grammar 2nd edition (TROG-II) [ Time Frame: 3 years ]
    This is a measure of receptive syntax skills (Bishop, 1983). Participants are asked to point to a picture (out of 4) that corresponds to a phrase or sentence spoken by the examiner. The total number of items correct (rather than blocks passed) will be used as the dependent variable, following the administration manual's ceiling rule.

  3. Linguistic functioning of the participants as assessed by the Peabody Picture Vocabulary Test-IV (PPVT-IV) [ Time Frame: 3 years ]
    This is a measure of receptive semantics, whereby the participant is asked to point to a picture (out of 4) that corresponds to a word spoken by the examiner. As this test has a 0.85 correlation with composite measures of Verbal IQ (i.e. from the Wechsler Intelligence Scale series), it can be used in conjunction with the Matrices subtest to estimate overall intellectual functioning. The total number of items correct was used as the dependent variable, following the administration manual's rules for basals and ceilings.

  4. Adaptive/Behavioral Functioning of the participants as assessed by the Scales of Independent Behavior-Revised (SIB-R) [ Time Frame: 3 years ]
    This is a measure of adaptive functioning that integrates information from 13 different domains (e.g., gross motor, social interaction, eating, toileting, dressing, personal self-care, etc.). It is in a questionnaire format, which a caregiver can complete while the participant is being tested. Standard scores for all indices will be derived from age norms that extend from birth to age 80, as these will be used as dependent variables.

  5. Exploratory study of electroencephalographic (EEG) Recordings of Evoked Potentials as potential biomarkers for the severity of the cognitive disability associated to Down syndrome and for the efficacy of the memantine treatment [ Time Frame: 3 years ]
    Auditory and visual evoked potential experiments will search for significant differences in peak amplitude and latency of MMNs in persons with Down syndrome in relation to typically developing persons without Down syndrome, and in participants with Down syndrome before and after memantine treatment

  6. Exploratory study of magnetic resonance imaging (MRI) as potential biomarkers for the severity of the cognitive disability associated to Down syndrome and for the efficacy of the memantine treatment [ Time Frame: 3 years ]
    MRI studies will be to provide precise source localization for the high-density EEG recordings of evoked potentials in a subset of 30-60 participants of this trial. In addition, these experiments will also produce high resolution sagittal slice images of the hippocampus and simple connectivity data sets



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   15 Years to 32 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Cytogenetically documented Trisomy 21 or Complete Unbalanced Translocation of Chromosome 21. Mosaic Trisomy 21 and partial translocations will be excluded from the study
  • No pregnancy by serum testing at screening. Females of child-bearing potential, sexually active must be practicing a reliable method of birth control. Urine pregnancy tests will be done at the 2 follow-up medical visits
  • Laboratory findings within normal limits or judged clinically insignificant at baseline
  • Vital signs within normal limits for age. Stable, medically treated hypotension will be allowed
  • ECG must demonstrate predominately normal sinus rhythm. Minor abnormalities documented as clinically insignificant will be allowed
  • Participants and their authorized representatives will provide written informed consent
  • Participants who have received any experimental drug for Down syndrome must undergo a washout
  • All participants must: Be in general good health as judged by the investigators; Be able to swallow oral medication; Have a reliable caregiver or family member who agrees to accompany participant to all visits, provide information about the participant as required by the protocol, and ensure compliance with the medication schedule; Be sufficiently proficient in English (USA) or Portuguese (Brazil) to reliably complete the study assessments
  • Age and gender matching participants without Down syndrome, must be: Males or females without Down syndrome aged-matching (within 3 years) participants with Down syndrome whom they are expected to serve as controls

Exclusion Criteria:

  • Participant weighing less than 40 kg
  • Current psychiatric or neurologic diagnosis other than Down syndrome (e.g., major depressive disorder, schizophrenia, bipolar disorder, autism, Alzheimer disease)
  • Current treatment with psychotropic drugs
  • Drug or alcohol abuse or dependence
  • Significant suicide risk or who would require treatment with electro-convulsive therapy or with psychotropic drugs during the study or who have received treatment with a depot neuroleptic drug within 6 months of entering the study.
  • Current or expected (within the next 6 months) hospitalization or residence in a skilled nursing facility (may reside in group homes or other residential settings with no skilled nursing)
  • Active or clinically significant conditions affecting absorption, distribution, or metabolism of study drug (e.g. inflammatory bowel disease or celiac disease)
  • Significant allergies to or other significant intolerance of memantine therapy, its ingredients, or with contraindications to memantine therapy as stated in the prescribing information
  • Participants who are expected to require general anesthetics during the course of the study
  • Presence or recent history of seizure disorder (< 3 years).
  • Clinically significant and/or clinically unstable systemic disease. (Those with controlled hypothyroidism must be on a stable dose of medication for at least 3 months prior to screening and have normal serum T-4 and TSH at screening; and those with controlled diabetes mellitus must have an HbA1c of < 8.0% and a random serum glucose value of < 170 mg/dl)
  • Severe infections or a major surgical operation within 3 months prior to screening
  • History of persistent cognitive deficits immediately following head trauma.
  • Donation of blood or blood products less that 30 days prior to screening, while participating in the study, or four weeks after completion of the study
  • Inability to comply with the protocol or perform the outcomes measures due to significant hearing or visual impairment or other issues judged relevant by the investigators
  • Exclusion criteria for controls without Down syndrome: History of substance abuse, major psychiatric disorder, attention deficit disorder, or learning disability; Beck Depression Score greater than 10; Exclusion criteria specific to MR scanning; Pregnancy; Neurologic history

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02304302


Contacts
Layout table for location contacts
Contact: Melissa R Stasko, JD 216-844-7281 Melissa.Stasko@case.edu
Contact: Alberto C Costa, MD, PhD 216-844-7395 Alberto.Costa@case.edu

Locations
Layout table for location information
United States, Ohio
University Hospitals Case Medical Center Recruiting
Cleveland, Ohio, United States, 44106
Contact: Melissa R Stasko, JD    216-844-7281    Melissa.Stasko@case.edu   
Contact: Alberto C Costa, MD, PhD    (216) 844-7395    Alberto.Costa@case.edu   
Principal Investigator: Alberto C Costa, MD, PhD         
Sub-Investigator: Nancy J Roizen, MD         
Sub-Investigator: Stephen L Ruedrich, MD         
Sub-Investigator: Hudson G Taylor, PhD         
Sub-Investigator: Katherine Koenig, PhD         
Sub-Investigator: Richard Boada, PhD         
Brazil
Sociedade Beneficente Israelita Brasileira Albert Einstein Recruiting
São Paulo, SP, Brazil, 05652- 900
Contact: Fernanda F Assir, MS    +1 55 11 2151-0724 ext 70724    fernanda.assir@einstein.br   
Principal Investigator: Ana C Brandão, MD         
Sub-Investigator: Patrícia Salmona, MD         
Sub-Investigator: Guilherme A Silveira, MD         
Sponsors and Collaborators
University Hospitals Cleveland Medical Center
Alana USA Foundation
Investigators
Layout table for investigator information
Principal Investigator: Alberto C Costa, MD, PhD University Hospitals Cleveland Medical Center
Study Director: Stephen L Ruedrich, MD University Hospitals Cleveland Medical Center

Publications:
Brandão IM, V. F, R. MR (2012) Prevalence of People with Down Syndrome in Brazil. In: Scientia Plena (www.scientiaplena.org.br).
Pueschel SM, Hopmann MR (1993) Speech and language abilities of children with Down syndrome. In: Enhancing children's communication: Research foundations for intervention (Kaisen AP, Gray DB, eds), pp 335-362. London: Brookes.

Layout table for additonal information
Responsible Party: Dr. Alberto Costa, MD, PhD, Professor of Pediatric Neurology, University Hospitals Cleveland Medical Center
ClinicalTrials.gov Identifier: NCT02304302     History of Changes
Other Study ID Numbers: 121971
First Posted: December 1, 2014    Key Record Dates
Last Update Posted: October 10, 2018
Last Verified: October 2018
Keywords provided by Dr. Alberto Costa, University Hospitals Cleveland Medical Center:
Memantine
Episodic Memory
CVLT
Hippocampus dependent memory
Short-term memory
Additional relevant MeSH terms:
Layout table for MeSH terms
Down Syndrome
Intellectual Disability
Syndrome
Disease
Pathologic Processes
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Abnormalities, Multiple
Congenital Abnormalities
Chromosome Disorders
Genetic Diseases, Inborn
Signs and Symptoms
Neurodevelopmental Disorders
Mental Disorders
Memantine
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents